• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

涉及利奈唑胺耐药表皮葡萄球菌的骨和关节感染的临床、细菌学和遗传学特征:法国参考中心的回顾性多中心研究。

Clinical, Bacteriological, and Genetic Characterization of Bone and Joint Infections Involving Linezolid-Resistant Staphylococcus epidermidis: a Retrospective Multicenter Study in French Reference Centers.

机构信息

Service des Maladies Infectieuses, Centre Hospitalier Régional Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Tours, France.

Service de Bactériologie et des Contrôles microbiologiques, Hôtel-Dieu, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Nantes, France.

出版信息

Microbiol Spectr. 2023 Jun 15;11(3):e0419022. doi: 10.1128/spectrum.04190-22. Epub 2023 May 3.

DOI:10.1128/spectrum.04190-22
PMID:37133395
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10269892/
Abstract

The choice of the best probabilistic postoperative antibiotics in bone and joint infections (BJIs) is still challenging. Since the implementation of protocolized postoperative linezolid in six French referral centers, linezolid-resistant multidrug-resistant Staphylococcus epidermidis (LR-MDRSE) strains were isolated in patients with BJI. We aimed here to describe clinical, microbiological, and molecular patterns associated with these strains. All patients with at least one intraoperative specimen positive for LR-MDRSE between 2015 and 2020 were included in this retrospective multicenter study. Clinical presentation, management, and outcome were described. LR-MDRSE strains were investigated by MIC determination for linezolid and other anti-MRSA antibiotics, characterization of genetic determinants of resistance, and phylogenetic analysis. Forty-six patients (colonization  = 10, infection  = 36) were included in five centers, 45 had prior exposure to linezolid, 33 had foreign devices. Clinical success was achieved for 26/36 patients. Incidence of LR-MDRSE increased over the study period. One hundred percent of the strains were resistant to oxazolidinones, gentamicin, clindamycin, ofloxacin, rifampicin, ceftaroline, and ceftobiprole, and susceptible to cyclins, daptomycin, and dalbavancin. Susceptibility to delafloxacin was bimodal. Molecular analysis was performed for 44 strains, and the main mutation conferring linezolid resistance was the 23S rRNA G2576T mutation. All strains belonged to the sequence type ST2 or its clonal complex, and phylogenetic analysis showed emergence of five populations corresponding geographically to the centers. We showed the emergence of new clonal populations of highly linezolid-resistant S. epidermidis in BJIs. Identifying patients at risk for LR-MDRSE acquisition and proposing alternatives to systematic postoperative linezolid use are essential. The manuscript describes the emergence of clonal linezolid-resistant strains of Staphylococcus epidermidis (LR-MDRSE) isolated from patients presenting with bone and joint infections. Incidence of LR-MDRSE increased over the study period. All strains were highly resistant to oxazolidinones, gentamicin, clindamycin, ofloxacin, rifampicin, ceftaroline, and ceftobiprole, but were susceptible to cyclins, daptomycin, and dalbavancin. Susceptibility to delafloxacin was bimodal. The main mutation conferring linezolid resistance was the 23S rRNA G2576T mutation. All strains belonged to the sequence type ST2 or its clonal complex, and phylogenetic analysis showed emergence of five populations corresponding geographically to the centers. LR-MDRSE bone and joint infections seem to be accompanied by an overall poor prognosis related to comorbidities and therapeutic issues. Identifying patients at risk for LR-MDRSE acquisition and proposing alternatives to systematic postoperative linezolid use become essential, with a preference for parenteral drugs such as lipopeptids or lipoglycopeptids.

摘要

在骨和关节感染(BJI)中选择最佳的概率术后抗生素仍然具有挑战性。自法国六个转诊中心实施术后利奈唑胺方案以来,BJI 患者中分离出了耐利奈唑胺的多药耐药表皮葡萄球菌(LR-MDRSE)菌株。我们旨在描述与这些菌株相关的临床、微生物学和分子模式。本回顾性多中心研究纳入了 2015 年至 2020 年间至少有一次术中标本 LR-MDRSE 阳性的所有患者。描述了临床表现、治疗和结局。通过测定利奈唑胺和其他抗耐甲氧西林金黄色葡萄球菌(MRSA)抗生素的 MIC、耐药基因的特征以及系统发育分析来研究 LR-MDRSE 菌株。在五个中心中,46 名患者(定植 10 例,感染 36 例)纳入本研究,45 名患者有过利奈唑胺暴露史,33 名患者有过外来设备。36 名患者中有 26 名临床治疗成功。在研究期间,LR-MDRSE 的发病率有所增加。所有菌株均对唑烷酮类、庆大霉素、克林霉素、氧氟沙星、利福平、头孢托罗、头孢比普和头孢噻肟耐药,对环丙沙星、达托霉素和达巴万星敏感。对德拉沙星的敏感性呈双峰模式。对 44 株进行了分子分析,导致利奈唑胺耐药的主要突变是 23S rRNA G2576T 突变。所有菌株均属于 ST2 或其克隆复合体,系统发育分析显示,与中心相对应的五个地理种群的出现。我们表明,BJIs 中耐利奈唑胺的表皮葡萄球菌新的克隆种群正在出现。确定 LR-MDRSE 获得的高危患者并提出系统术后使用利奈唑胺的替代方案至关重要。本文描述了从患有骨和关节感染的患者中分离出的耐利奈唑胺的表皮葡萄球菌(LR-MDRSE)的克隆株的出现。在研究期间,LR-MDRSE 的发病率有所增加。所有菌株对唑烷酮类、庆大霉素、克林霉素、氧氟沙星、利福平、头孢托罗和头孢比普均高度耐药,但对环丙沙星、达托霉素和达巴万星敏感。对德拉沙星的敏感性呈双峰模式。导致利奈唑胺耐药的主要突变是 23S rRNA G2576T 突变。所有菌株均属于 ST2 或其克隆复合体,系统发育分析显示,与中心相对应的五个地理种群的出现。LR-MDRSE 骨和关节感染似乎与与合并症和治疗问题相关的整体预后不良有关。确定 LR-MDRSE 获得的高危患者并提出系统术后使用利奈唑胺的替代方案变得至关重要,首选的药物为脂肽或脂糖肽等注射用药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e04/10269892/8db2357d02bd/spectrum.04190-22-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e04/10269892/2adc6afb6195/spectrum.04190-22-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e04/10269892/37dadf4ab853/spectrum.04190-22-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e04/10269892/8db2357d02bd/spectrum.04190-22-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e04/10269892/2adc6afb6195/spectrum.04190-22-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e04/10269892/37dadf4ab853/spectrum.04190-22-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e04/10269892/8db2357d02bd/spectrum.04190-22-f003.jpg

相似文献

1
Clinical, Bacteriological, and Genetic Characterization of Bone and Joint Infections Involving Linezolid-Resistant Staphylococcus epidermidis: a Retrospective Multicenter Study in French Reference Centers.涉及利奈唑胺耐药表皮葡萄球菌的骨和关节感染的临床、细菌学和遗传学特征:法国参考中心的回顾性多中心研究。
Microbiol Spectr. 2023 Jun 15;11(3):e0419022. doi: 10.1128/spectrum.04190-22. Epub 2023 May 3.
2
Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections.凝固酶阴性葡萄球菌和侵袭性感染中介导林可霉素耐药的耐甲氧西林金黄色葡萄球菌的敏感性趋势。
Int J Antimicrob Agents. 2015 Dec;46(6):622-30. doi: 10.1016/j.ijantimicag.2015.07.022. Epub 2015 Sep 25.
3
Mechanisms of Linezolid Resistance Among Clinical spp. in Spain: Spread of Methicillin- and Linezolid-Resistant ST2.西班牙临床 spp.中利奈唑胺耐药的机制:耐甲氧西林和利奈唑胺的 ST2 传播。
Microb Drug Resist. 2021 Feb;27(2):145-153. doi: 10.1089/mdr.2020.0122. Epub 2020 May 22.
4
Persistence of a multidrug-resistant worldwide-disseminated methicillin-resistant Staphylococcus epidermidis clone harbouring the cfr linezolid resistance gene in a French hospital with evidence of interspecies transfer to several Staphylococcus aureus lineages.耐甲氧西林表皮葡萄球菌在法国医院中的持续存在,该菌为一种具有 cfr 基因的多药耐药、世界范围传播的克隆株,有证据表明其可向几种金黄色葡萄球菌谱系发生种间转移。
J Antimicrob Chemother. 2022 Jun 29;77(7):1838-1846. doi: 10.1093/jac/dkac119.
5
Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitals.美国医院表皮葡萄球菌临床分离株的分子流行病学研究。
Antimicrob Agents Chemother. 2012 Sep;56(9):4656-61. doi: 10.1128/AAC.00279-12. Epub 2012 Jun 11.
6
Endemic linezolid-resistant Staphylococcus epidermidis in a critical care unit.重症监护病房中的地方性耐利奈唑胺表皮葡萄球菌
Eur J Clin Microbiol Infect Dis. 2009 May;28(5):527-33. doi: 10.1007/s10096-008-0657-5. Epub 2008 Nov 5.
7
Persistence and evolution of linezolid- and methicillin-resistant Staphylococcus epidermidis ST2 and ST5 clones in an Italian hospital.意大利一家医院中耐利奈唑胺和耐甲氧西林表皮葡萄球菌ST2和ST5克隆的持续性和演变
J Glob Antimicrob Resist. 2024 Mar;36:358-364. doi: 10.1016/j.jgar.2024.01.020. Epub 2024 Feb 7.
8
Nosocomial outbreak of methicillin- and linezolid-resistant Staphylococcus epidermidis associated with catheter-related infections in intensive care unit patients.耐甲氧西林和利奈唑胺的表皮葡萄球菌医院感染爆发与重症监护病房患者的导管相关感染有关。
Int J Med Microbiol. 2011 Apr;301(4):354-8. doi: 10.1016/j.ijmm.2010.11.001. Epub 2011 Jan 14.
9
Molecular epidemiology of coagulase-negative bloodstream isolates: detection of Staphylococcus epidermidis ST2, ST7 and linezolid-resistant ST23.凝固酶阴性血流分离株的分子流行病学:表皮葡萄球菌 ST2、ST7 和耐利奈唑烷 ST23 的检测。
Braz J Infect Dis. 2016 Sep-Oct;20(5):419-28. doi: 10.1016/j.bjid.2016.05.007. Epub 2016 Jul 6.
10
Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.首次报告耐利奈唑酮的金黄色葡萄球菌爆发与 cfr 基因介导的利奈唑酮耐药有关。
Clin Infect Dis. 2010 Mar 15;50(6):821-5. doi: 10.1086/650574.

引用本文的文献

1
Dalbavancin-resistant selection following a prosthetic joint infection: phenotypic and genomic characterization.人工关节感染后达巴万星耐药性选择:表型和基因组特征分析
JAC Antimicrob Resist. 2024 Oct 18;6(5):dlae163. doi: 10.1093/jacamr/dlae163. eCollection 2024 Oct.
2
Investigation of a linezolid-resistant outbreak in a French hospital: phenotypic, genotypic, and clinical characterization.法国一家医院耐利奈唑胺疫情调查:表型、基因型及临床特征分析
Front Microbiol. 2024 Sep 11;15:1455945. doi: 10.3389/fmicb.2024.1455945. eCollection 2024.
3
Genetic Diversification and Resistome of Coagulase-Negative Staphylococci from Nostrils of Healthy Dogs and Dog-Owners in La Rioja, Spain.

本文引用的文献

1
Genomics of Staphylococcus aureus and Staphylococcus epidermidis from Periprosthetic Joint Infections and Correlation to Clinical Outcome.假体周围关节感染的金黄色葡萄球菌和表皮葡萄球菌的基因组学及其与临床结果的相关性。
Microbiol Spectr. 2022 Aug 31;10(4):e0218121. doi: 10.1128/spectrum.02181-21. Epub 2022 Jun 28.
2
Emergence of methicillin-resistant Staphylococcus epidermidis resistant to linezolid: activity of ceftaroline versus ceftobiprole in a French University Hospital.对利奈唑胺耐药的耐甲氧西林表皮葡萄球菌的出现:法国大学医院中头孢洛林与头孢比普对其的活性比较
Int J Antimicrob Agents. 2022 Sep;60(3):106613. doi: 10.1016/j.ijantimicag.2022.106613. Epub 2022 Jun 9.
3
西班牙拉里奥哈地区健康犬及其主人鼻孔中凝固酶阴性葡萄球菌的遗传多样性和耐药组
Pathogens. 2024 Mar 5;13(3):229. doi: 10.3390/pathogens13030229.
4
Updated Review on Clinically-Relevant Properties of Delafloxacin.关于德拉氟沙星临床相关特性的最新综述
Antibiotics (Basel). 2023 Jul 28;12(8):1241. doi: 10.3390/antibiotics12081241.
5
Molecular Characterization of Clinical Linezolid-Resistant in a Tertiary Care Hospital.三级护理医院临床耐利奈唑胺菌株的分子特征分析
Microorganisms. 2023 Jul 14;11(7):1805. doi: 10.3390/microorganisms11071805.
Persistence of a multidrug-resistant worldwide-disseminated methicillin-resistant Staphylococcus epidermidis clone harbouring the cfr linezolid resistance gene in a French hospital with evidence of interspecies transfer to several Staphylococcus aureus lineages.
耐甲氧西林表皮葡萄球菌在法国医院中的持续存在,该菌为一种具有 cfr 基因的多药耐药、世界范围传播的克隆株,有证据表明其可向几种金黄色葡萄球菌谱系发生种间转移。
J Antimicrob Chemother. 2022 Jun 29;77(7):1838-1846. doi: 10.1093/jac/dkac119.
4
Genomic and Phenotypic Analysis of Linezolid-Resistant in a Tertiary Hospital in Innsbruck, Austria.奥地利因斯布鲁克一家三级医院中耐利奈唑胺的基因组和表型分析。
Microorganisms. 2021 May 10;9(5):1023. doi: 10.3390/microorganisms9051023.
5
Comparative genomics of from prosthetic-joint infections and nares highlights genetic traits associated with antimicrobial resistance, not virulence.从人工关节感染和鼻腔中分离出的 的比较基因组学研究突出了与抗菌药物耐药性相关的遗传特征,而不是毒力。
Microb Genom. 2021 Feb;7(2). doi: 10.1099/mgen.0.000504.
6
Epidemiology of complex bone and joint infections in France using a national registry: The CRIOAc network.法国使用国家登记处研究复杂骨和关节感染的流行病学:CRIOAc 网络。
J Infect. 2021 Feb;82(2):199-206. doi: 10.1016/j.jinf.2020.12.010. Epub 2020 Dec 19.
7
Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections.头孢托罗匹酯:一种潜在的人工关节感染术后经验性单药治疗选择。
Ann Clin Microbiol Antimicrob. 2020 Mar 21;19(1):9. doi: 10.1186/s12941-020-00351-5.
8
Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.不同抗葡萄球菌疗法单独或联合应用于无植入物的耐甲氧西林表皮葡萄球菌骨髓炎大鼠模型中的活性
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01865-19.
9
Probabilistic chemotherapy in knee and hip replacement infection: the place of linezolid.膝关节和髋关节置换术后感染的化疗概率:利奈唑胺的地位。
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1659-1663. doi: 10.1007/s10096-019-03594-z. Epub 2019 Jun 15.
10
Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting.评估利奈唑胺和替加环素在骨和关节感染环境中清除骨内和生物膜内金黄色葡萄球菌的能力。
J Antimicrob Chemother. 2019 Mar 1;74(3):625-632. doi: 10.1093/jac/dky473.